GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Legend Biotech Corp (NAS:LEGN) » Definitions » Short-Term Debt

Legend Biotech (Legend Biotech) Short-Term Debt : $0.0 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Legend Biotech Short-Term Debt?

Legend Biotech's Short-Term Debt for the quarter that ended in Mar. 2024 was $0.0 Mil.


Legend Biotech Short-Term Debt Historical Data

The historical data trend for Legend Biotech's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Legend Biotech Short-Term Debt Chart

Legend Biotech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial - - - - -

Legend Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Legend Biotech Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Legend Biotech Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Legend Biotech's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Legend Biotech (Legend Biotech) Business Description

Traded in Other Exchanges
Address
2101 Cottontail Lane, Somerset, NJ, USA, 08873
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America.